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FIGURE 1 Individual Changes in Apnea–Hypopnea Index and
Systolic Blood Pressure Obtained at Baseline and at the
3-Month Follow-Up Examination in Patients With and
Without PFO
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Individual changes in the apnea–hypopnea index (upper panel)
obtained at baseline and at the 3-month follow-up examination
in patients with patent foramen ovale (PFO) and in patients
without PFO. Changes in nocturnal systolic blood pressure and in
transtricuspid right ventricular (RV) to right atrial (RA) systolic
pressure gradient (middle and lower panels) at baseline and at
the 3-month follow-up examination in patients with and without
PFO. Error lines indicate mean  SD.
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269–78.Emergency Department
Management of
Atrial Fibrillation in the
United States Versus
Ontario, CanadaSurvey data suggest that there is considerable inter-
national variation in the emergency department (ED)
management of patients with atrial ﬁbrillation (AF)
(1–3). Hospitalization is common in the United States
(2), where nearly 70% of ED visits for AF end in
hospitalization (2,3); this has remained constant
since 2000 (2,3). By comparison, in Canada’s most
populous province <40% of individual AF patients
were admitted in 2010 (1), which had dropped by 10%
since 2002 (1). However, no direct intercountry com-
parisons have been published. Our objective was to
directly compare ED AF visits and their associated
management strategies in the United States and the
province of Ontario, Canada.
We conducted a cross-sectional study of ED visits
with a primary diagnosis of AF between January 1,
2007, and December 31, 2009, in the U.S. Nationwide
Emergency Department Sample (NEDS) and the
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Ambulatory Care Reporting System (CIHI-NACRS).
The U.S. cohort was deﬁned in NEDS as visits made by
patients age $18 years with the primary (ﬁrst) ED
diagnosis listed as AF, identiﬁed by the International
Classiﬁcation of Diseases-Ninth Revision (ICD-9)
Clinical Modiﬁcation code 427.31. The Ontario cohort
was deﬁned as ED visits made by patients age $18
years with the primary ED diagnosis listed as AF,
identiﬁed by the ICD-10 code I480 in CIHI-NACRS.
Ontario has 13 million residents and is the only Cana-
dian province with complete ED data in CIHI-NACRS.
The methods for measuring comorbidities and ED
cardioversions have been previously described (1,2).
The primary outcome measure was the proportion
of ED AF visits that resulted in hospitalization in the
United States versus Ontario. Secondary outcomes
included deaths in the ED and ED cardioversions in
the United States versus Ontario. Rate ratios (RR)
were used to compare outcomes in the United States
and Ontario using the Ontario cohort as the referent.
There were an estimated 1,320,123 ED visits for AF in
the United States, and 56,413 visits in Ontario. ED visits
for AF resulted in hospitalization nearly twice as often
in the United States, comparedwith the Ontario cohort
(RR: 1.86; 95% conﬁdence interval [CI]: 1.84 to
1.89). The greatest intercountry differences in hos-
pitalization were among patients age <65 years
(Table 1). In the United States, these patients had a
similar likelihood of hospitalization as their older
U.S. counterparts, whereas the younger cohort in
Ontario was far less likely to be hospitalized than
older patients. ED deaths were rare in both settings,
whereas ED cardioversions were nearly one-half asTABLE 1 Characteristics of Patients Making ED Visits for AF, in the U
United States
Age, yrs 71.1 (59.3, 80.4)
Female 52.5
ED visit characteristics
ED/hospital type Large metropolitan: 48.2
Teaching hospital: 34.4
Rural: 18.5
Weekend visit 25.1
Admitted to hospital (overall) 69.3
Admitted to hospital within age groups
Ages 18–64 yrs 62.7
Ages 65–84 yrs 71.0
Ages $85 yrs 78.3
ED cardioversion 5.5
Died in ED 0.05
Values are median (interquartile range) or %, except as noted.
AF ¼ atrial ﬁbrillation; ED ¼ emergency department.frequent in the United States (RR: 0.53, 95% CI: 0.51
to 0.54). Older patients are at increased risk of
death following the ED visit for AF compared with
younger patients, which may justify the need for
hospitalization. The rationale behind admitting the
majority of younger patients with AF, however, is
less evident. Hospitalizations constitute the large
majority of the total cost of AF management (4). In
addition to exposing patients to the risk of hospital-
associated complications, the ﬁnancial costs of
admission are both tremendous and not obviously
justiﬁed. Differences in the ﬁnancial incentives (and
disincentives) for hospitals to admit low-risk pa-
tients in the United States and Canada may
contribute to the variation in hospitalization. Future
studies are needed to examine the etiologies.
This work used large national and provincial
administrative databases; although it facilitates na-
tional comparisons, it is subject to limitations. Our
evaluation of comorbidities relies on the NEDS site
administrators to record these diseases in the
remaining 14 diagnoses ﬁelds. This increases the po-
tential for underreporting, which may have contrib-
uted to the lower levels of prior stroke, as well as
other comorbidities, in the U.S. cohort. NEDS has no
data on medications or outcomes after the patient is
discharged from hospital.
The proportion of ED visits for AF that result in
hospitalization was almost double in the United
States compared with Canada’s most populous prov-
ince, with the greatest intercountry differences
among visits made by patients age <65 years. There is
substantial variation between countries in the ED
management of AF: such intercountry comparisonsnited States and Ontario, Canada
95% Conﬁdence
Interval Ontario, Canada
95% Conﬁdence
Interval
72.0 (60.0, 80.0)
52.2–52.8 51.2 50.8–51.6
45.8–50.5 Community: 73.9 73.5–74.3
32.0–36.8 Teaching hospital: 18.3 18.0–18.6
17.1–19.8 Small: 7.8 7.6–8.0
24.9–25.3 24.6 24.2–24.9
68.3–70.3 37.3 36.9–37.7
61.5–63.9 26.1 25.5–26.7
70.0–72.1 39.7 39.1–40.2
77.4–79.2 56.1 54.9–57.2
4.7–6.2 10.4 10.1–10.6
0.04–0.06 0.04 0.02–0.06
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Tetralogy, Transposition, and Truncus, Too?The term “structural heart disease” entered the adult
cardiology lexicon in 1999 and currently encompasses
the base of knowledge and competencies surrounding
noncoronary cardiac procedures such as transcatheter
aortic valve replacement (TAVR), percutaneous mitralrepair, and left atrial appendage exclusion. We and
others have detected an indiscriminant trend, how-
ever, to use the phrase “structural heart disease”
(SHD) to include congenital heart disease (CHD). The
recent editorial by Drs. Yadav, Halim, and Vavalle (1)
in which the authors make an impassioned plea for
improved adult SHD interventional training is a
recent example, because throughout the paper, SHD
and CHD are conﬂated. We wish to point out the
important distinction between SHD and CHD in cur-
rent vernacular, so as to avoid further sensed com-
petition and to promote best patient outcomes across
all cardiac specialties.
CHD is an important and distinct subset of SHD.
First, it challenges clinicians with a combination of
complex pathophysiology, anatomy, and natural and
unnatural history that rarely is incorporated into
traditional cardiovascular medicine training. Second,
many types of CHD can be treated with a well-
developed array of interventional transcatheter ther-
apies that are unique to the ﬁeld of CHD and that
continue to evolve along their own distinct pathway
outside of SHD. Indeed, percutaneous treatment of
CHD is a mature specialty. Third, patients with CHD
beneﬁt from established clinical and training pro-
grams with dedicated focus on their complex CHD
structural lesions. There is an entire body of knowl-
edge in the ﬁeld of pediatric and adult CHD (ACHD)
that addresses congenital anatomy, pathophysiology,
percutaneous and surgical palliation, and lifelong
cardiovascular issues that span the spectrum of car-
diovascular medicine (heart failure, arrhythmias,
cardiopulmonary hemodynamics, valvular heart dis-
ease, aortic disease, peripheral and pulmonary vas-
cular disease). Just as there is requisite competency in
critical understanding of aortic valve anatomy, phys-
iology, and indications for replacement before per-
forming the TAVR procedure, CHD interventionalists
must be fully competent in critical aspects of CHD
before performing procedures. Finally, CHD is its own
specialty and is recognized as such. The American
College of Cardiology provides a professional home to
its pediatric and ACHD care providers within the Adult
Congenital and Pediatric Cardiology Section, founded
in 2005. The American Board of Internal Medicine has
established ACHD board certiﬁcation, and the
Accreditation Council for Graduate Medical Education
is in the ﬁnal stages of deﬁning ACHD training re-
quirements, which will require 24 months of fellow-
ship training after general cardiology or pediatric
cardiology, to be competent in the ﬁeld of ACHD and to
be board eligible for the certifying exam.
Therefore, for the sake of best care and outcomes for
all our patients, we ask clinicians, authors, and editors
